By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Pacritinib (systemic) (monograph)
Drugs

Pacritinib (systemic) (monograph)

https://themeditary.com/drug/pacritinib-systemic-monograph-18626.html
Medically Reviewed by Oluni Odunlami, MD TheMediTary.Com | Reviewed: Sep 26, 2023  Additional Content by TheMediTary.Com

Generic name: vonjo

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Vonjo, Pacritinib

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Pacritinib (systemic) (monograph)?

Introduction

Antineoplastic agent; selective inhibitor of Janus kinase (JAK) 2, mutant JAK2V617F, and FMS-like tyrosine kinase (FLT) 3.

Uses for Pacritinib (Systemic)

Intermediate- or High-Risk Myelofibrosis

Treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count <50,000/mm3.

Approved under accelerated approval based on proportion of patients achieving ≥35% reduction from baseline in spleen volume; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials(s).

Designated an orphan drug by FDA for this use.

Myelofibrosis drug treatment is based upon prognostic risk models. Observation alone is advised for asymptomatic low-risk patients; for patients with higher-risk disease, allogeneic hematopoietic stem cell transplant (ASCT) is the preferred treatment. In patients who are not candidates for transplant, JAK inhibitors (i.e., ruxolitinib, pacritinib, fedratinib) may be used to provide symptom-based management and improve quality of life.

The first JAK inhibitors approved for myelofibrosis (e.g., ruxolitinib, feratinib) are associated with significant risks of hematologic toxicities. Pacritinib is an additional therapeutic option for patients with symptomatic myelofibrosis who have severe thrombocytopenia. Specific indications and toxicity profiles of the currently available JAK2 inhibitors differ; treatment should be individualized.

Related/similar drugs

Jakafi, ruxolitinib, Vonjo, pacritinib, Inrebic, fedratinib

Pacritinib (Systemic) Dosage and Administration

General

Pretreatment Screening

  • Perform CBC including WBC differential and platelet count.

  • Perform coagulation testing (prothrombin time [PT], activated partial thromboplastin time [aPTT], thrombin time [TT], and international normalized ratio [INR]).

  • Perform baseline ECG.

Patient Monitoring

  • Monitor CBC including WBC differential and platelet count as clinically indicated during drug therapy.

  • Monitor ECG as clinically indicated during drug therapy.

  • Monitor for signs or symptoms of infection during drug therapy.

Other General Considerations

  • Discontinue or taper other kinase inhibitors according to the specific prescribing information for that drug before pacritinib initiation.

  • Discontinue pacritinib 7 days prior to elective surgery or invasive procedures because of the risk of hemorrhage; resume drug only after hemostasis is assured.

Administration

Oral Administration

Administer orally; take with or without food.

Swallow whole; do not open, break, or chew the capsules.

If a dose is missed, the dose should be taken at the next scheduled time. Do not take an additional dose.

Dosage

Available as pacritinib citrate; dosage expressed in terms of pacritinib.

Adults

Intermediate- or High-Risk Myelofibrosis
Oral

200 mg twice daily.

Dosage Modification for Toxicity
Oral

If adverse reactions occur during pacritinib therapy, temporary interruption of therapy, dosage reduction, and/or discontinuance of the drug may be necessary. If dosage reduction is required, the dosage of pacritinib should be reduced as described in Table 1.

Table 1: Recommended Dosage Reduction for Pacritinib Toxicity.1

Dose Reduction Level

Dosage Reduction after Recovery from Toxicity (Initial Dosage = 200 mg twice daily)

First

100 mg twice daily

Second

100 mg once daily

Third

Discontinue drug

The following table indicates the recommended dosage modification (i.e., temporary interruption of therapy, dosage reduction, discontinuance of therapy) for certain adverse effects according to severity.

Table 2. Dosage Modification for Pacritinib Toxicity.1

Adverse Reaction and Severity

Modification

Diarrhea

New onset: Initiate anti-diarrheal medications; encourage adequate oral hydration

Grade 3 or 4: Withhold therapy until diarrhea improves to grade 1 or lower; resume at last given dose. Intensify antidiarrheal medications and provide fluid replacement. If diarrhea recurs, withhold therapy until resolution to grade 1 or lower or baseline; resume therapy at 50% of the last dose once toxicity has resolved. Concomitant antidiarrheal treatment is required for patients resuming drug.

Thrombocytopenia

Clinically significant worsening of thrombocytopenia that lasts >7 days: Withhold therapy until thrombocytopenia resolves; resume at 50% of the last dosage. If toxicity recurs, withhold therapy until thrombocytopenia resolves; resume at 50% of the last dosage.

Hemorrhage

Moderate bleeding; intervention indicated: Withhold therapy until bleeding resolves; resume at same dosage. If hemorrhage recurs, withhold therapy until bleeding resolves; resume at 50% of the last dosage

Severe bleeding; transfusion, invasive intervention, or hospitalization indicated: Withhold therapy until bleeding resolves; resume at 50% of the last dosage. If bleeding recurs, discontinue therapy.

Life-threatening bleeding; urgent intervention indicated: Discontinue therapy.

Prolonged QT Interval

QTc prolongation >500 msec or >60 msec from baseline: Withhold therapy. If QTc prolongation resolves to ≤480 msec or baseline within 1 week, resume at same dosage; If time to resolution is >1 week, resume therapy at a reduced dosage.

Special Populations

Hepatic Impairment

No specific dosage recommendations for patients with hepatic impairment.

Patients with Child-Pugh class B: Avoid use.

Patients with Child-Pugh class C: Avoid use.

Renal Impairment

No specific dosage recommendations for patients with renal impairment.

Patients with eGFR (MDRD) <30 mL/minute: Avoid use.

Geriatric Use

No specific dosage recommendations for geriatric patients.

Detailed Pacritinib dosage information

Warnings

Contraindications

  • Concomitant use of strong CYP3A4 inhibitors or inducers.

Warnings/Precautions

Hemorrhage

Serious and fatal hemorrhage reported in patients with platelet counts <100,000/mm3.

Dosage reduction, interruption, or permanent discontinuation may be required.

Avoid use in patients with active bleeding.

Hold 7 days prior to any planned surgical or invasive procedures.

Assess platelet counts periodically, as clinically indicated.

Manage hemorrhage using treatment interruption and medical intervention.

Diarrhea

Diarrhea occurs frequently; median time to resolution was 2 weeks. Incidence decreases over time; treatment interruption may be necessary.

Control pre-existing diarrhea before starting treatment. Manage with antidiarrheal medications, fluid replacement, and dosage modification.

Treat with antidiarrheal medications promptly at the first onset of symptoms. Interrupt or reduce dosage in patients with significant diarrhea despite optimal supportive care.

Thrombocytopenia

Worsening thrombocytopenia reported. Pacritinib interruption and dosage reduction may be required.

Monitor platelet count prior to treatment and as clinically indicated during treatment.

Interrupt pacritinib in patients with clinically significant worsening of thrombocytopenia that lasts for >7 days. Once the toxicity has resolved, restart at 50% of the last given dosage.

If toxicity recurs, hold pacritinib; resume the drug at 50% of the last given dose once the toxicity has resolved.

Prolonged QT Interval

Can cause prolongation of the QTc interval. QTc prolongation of >500 msec or increase from baseline by ≥60 msec was higher in pacritinib-treated patients than patients in the control group.

Adverse reactions related to QTc prolongation reported; no cases of torsades de pointes reported.

Avoid use in patients with a baseline QTc of >480 msec. Avoid concomitant use of drugs with significant potential for QTc prolongation.

Correct hypokalemia prior to and during treatment. Manage QTc prolongation with dose interruption and electrolyte management.

Major Adverse Cardiac Events (MACE)

Increased risk of major adverse cardiovascular events (MACE), including cardiovascular death, MI, and stroke, reported in patients receiving other JAK inhibitors for the treatment of rheumatoid arthritis.

Consider risks and benefits of pacritinib prior to initiating or continuing therapy, particularly in patients who are current or past smokers and in those with other cardiovascular risk factors. Advise patient to seek immediate medical attention if symptoms of serious cardiovascular events occur.

Thromboembolic Events

Serious and sometimes fatal thromboembolic events, including DVT, PE, and arterial thrombosis in the extremities, reported in patients receiving other JAK inhibitors for the treatment of rheumatoid arthritis.

Promptly evaluate and treat any patients who develop symptoms of thrombosis during treatment with pacritinib.

Secondary Malignancies

Another JAK inhibitor increased risk of lymphoma and other malignancies, excluding non-melanoma skin cancer (NMSC), in patients with rheumatoid arthritis.

Consider risks and benefits of pacritinib prior to initiating therapy or when considering whether to continue pacritinib, particularly in patients with a known malignancy (other than successfully treated NMSC), in those who develop a malignancy, and those who are current or past smokers.

Risk of Infection

Another JAK inhibitor increased the risk of serious infections (compared to best available therapy) in patients with myeloproliferative neoplasms.

Serious bacterial, mycobacterial, fungal, and viral infections may occur.

Resolve active serious infections prior to initiating pacritinib. Observe patients for signs and/or symptoms of infection and promptly initiate appropriate treatment.

Employ active surveillance and prophylactic antibiotics according to clinical guidelines.

Interactions with CYP3A4 Inhibitors or Inducers

Concomitant use with strong CYP3A4 inhibitors or inducers contraindicated.

Avoid concomitant use with moderate CYP3A4 inhibitors or inducers.

Specific Populations

Pregnancy

Animal studies revealed maternal toxicity and embryonic and fetal loss at dosages considerably lower than the recommended human dose.

No available human data to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes related to the use of pacritinib.

Advise pregnant women of the potential risk to a fetus. Consider benefits and risks of pacritinib for the mother and possible risks to the fetus when prescribing pacritinib to a pregnant woman.

Lactation

No data on presence of pacritinib in either human or animal milk, effects on the breast-fed child, or effects on milk production.

Females should not breast-feed while receiving the drug, and for at least 2 weeks after the last dose.

Females and Males of Reproductive Potential

Reduced male mating and fertility in mice. Pacritinib may impair male fertility in humans.

Pediatric Use

Safety and efficacy not established.

Geriatric Use

Experience in patients ≥65 years of age is insufficient to determine whether geriatric patients respond differently than younger individuals.

Hepatic Impairment

Mild (Child-Pugh class A): AUC decreased by 8.5%.

Moderate (Child-Pugh class B): AUC decreased by 36%. Avoid use.

Severe hepatic impairment (Child-Pugh class C): AUC decreased by 45%. Avoid use.

Renal Impairment

eGFR 15 to 29 mL/minute: Peak plasma concentration and AUC of pacritinib increased by approximately 30%. Avoid use.

eGFR <15 mL/minute on hemodialysis: Peak plasma concentration and AUC of pacritinib increased by approximately 30%. Avoid use.

Common Adverse Effects

Adverse effects (≥20%): Diarrhea, thrombocytopenia, nausea, anemia, peripheral edema.

How should I use Pacritinib (systemic) (monograph)

General

Pretreatment Screening

  • Perform CBC including WBC differential and platelet count.

  • Perform coagulation testing (prothrombin time [PT], activated partial thromboplastin time [aPTT], thrombin time [TT], and international normalized ratio [INR]).

  • Perform baseline ECG.

Patient Monitoring

  • Monitor CBC including WBC differential and platelet count as clinically indicated during drug therapy.

  • Monitor ECG as clinically indicated during drug therapy.

  • Monitor for signs or symptoms of infection during drug therapy.

Other General Considerations

  • Discontinue or taper other kinase inhibitors according to the specific prescribing information for that drug before pacritinib initiation.

  • Discontinue pacritinib 7 days prior to elective surgery or invasive procedures because of the risk of hemorrhage; resume drug only after hemostasis is assured.

Administration

Oral Administration

Administer orally; take with or without food.

Swallow whole; do not open, break, or chew the capsules.

If a dose is missed, the dose should be taken at the next scheduled time. Do not take an additional dose.

Dosage

Available as pacritinib citrate; dosage expressed in terms of pacritinib.

Adults

Intermediate- or High-Risk Myelofibrosis
Oral

200 mg twice daily.

Dosage Modification for Toxicity
Oral

If adverse reactions occur during pacritinib therapy, temporary interruption of therapy, dosage reduction, and/or discontinuance of the drug may be necessary. If dosage reduction is required, the dosage of pacritinib should be reduced as described in Table 1.

Table 1: Recommended Dosage Reduction for Pacritinib Toxicity.1

Dose Reduction Level

Dosage Reduction after Recovery from Toxicity (Initial Dosage = 200 mg twice daily)

First

100 mg twice daily

Second

100 mg once daily

Third

Discontinue drug

The following table indicates the recommended dosage modification (i.e., temporary interruption of therapy, dosage reduction, discontinuance of therapy) for certain adverse effects according to severity.

Table 2. Dosage Modification for Pacritinib Toxicity.1

Adverse Reaction and Severity

Modification

Diarrhea

New onset: Initiate anti-diarrheal medications; encourage adequate oral hydration

Grade 3 or 4: Withhold therapy until diarrhea improves to grade 1 or lower; resume at last given dose. Intensify antidiarrheal medications and provide fluid replacement. If diarrhea recurs, withhold therapy until resolution to grade 1 or lower or baseline; resume therapy at 50% of the last dose once toxicity has resolved. Concomitant antidiarrheal treatment is required for patients resuming drug.

Thrombocytopenia

Clinically significant worsening of thrombocytopenia that lasts >7 days: Withhold therapy until thrombocytopenia resolves; resume at 50% of the last dosage. If toxicity recurs, withhold therapy until thrombocytopenia resolves; resume at 50% of the last dosage.

Hemorrhage

Moderate bleeding; intervention indicated: Withhold therapy until bleeding resolves; resume at same dosage. If hemorrhage recurs, withhold therapy until bleeding resolves; resume at 50% of the last dosage

Severe bleeding; transfusion, invasive intervention, or hospitalization indicated: Withhold therapy until bleeding resolves; resume at 50% of the last dosage. If bleeding recurs, discontinue therapy.

Life-threatening bleeding; urgent intervention indicated: Discontinue therapy.

Prolonged QT Interval

QTc prolongation >500 msec or >60 msec from baseline: Withhold therapy. If QTc prolongation resolves to ≤480 msec or baseline within 1 week, resume at same dosage; If time to resolution is >1 week, resume therapy at a reduced dosage.

Special Populations

Hepatic Impairment

No specific dosage recommendations for patients with hepatic impairment.

Patients with Child-Pugh class B: Avoid use.

Patients with Child-Pugh class C: Avoid use.

Renal Impairment

No specific dosage recommendations for patients with renal impairment.

Patients with eGFR (MDRD) <30 mL/minute: Avoid use.

Geriatric Use

No specific dosage recommendations for geriatric patients.

Detailed Pacritinib dosage information
Pacritinib (systemic) (monograph) Dosage information (more detail)

What other drugs will affect Pacritinib (systemic) (monograph)?

Metabolized mainly by CYP3A4.

Pacritinib inhibits CYP1A2, 2C19 and 3A4 and to a lesser extent CYP1A2, 2B6, 2C8, 2C9, and 2D6.

Pacritinib is an inducer of CYP1A2 and 3A4.

Pacritinib is not a substrate of breast cancer resistance protein (BCRP), multidrug resistance-associated protein (MRP) 2, organic anion-transporters (OAT) 1 and 3, organic anion-transporting polypeptides (OATP) 1B1 and 1B3, organic cation transporters (OCT) 1 and 2, or P-glycoprotein (P-gp).

Pacritinib is an inhibitor of BCRP, OCT1, OCT2, and P-gp, but not an inhibitor of bile salt export pump (BSEP), MRP2, OAT1, or OAT3.

Drugs Affecting Hepatic Microsomal Enzymes

Potent CYP3A4 inhibitors: Pharmacokinetic interaction (increased pacritinib peak plasma concentrations and AUC). Concomitant use is contraindicated.

Moderate CYP3A4 inhibitors: Pharmacokinetic interaction not studied. Avoid.

Potent CYP3A4 inducers: Pharmacokinetic interaction (decreased pacritinib peak plasma concentrations and AUC). Concomitant use is contraindicated.

Moderate CYP3A4 inducers: Pharmacokinetic interaction not studied. Avoid.

Drugs Metabolized by Hepatic Microsomal Enzymes

CYP1A2 substrates: Pharmacokinetic interaction (increased substrate plasma concentration). Avoid co-administration.

CYP 3A4 substrates: Pharmacokinetic interaction (increased substrate plasma concentration). Avoid co-administration.

Drugs Affecting or Affected by Transport Systems

P-gp substrates: Pharmacokinetic interaction (increased substrate plasma concentration). Avoid co-administration.

BCRP substrates: Pharmacokinetic interaction (increased substrate plasma concentration). Avoid co-administration.

OCT1 substrates: Pharmacokinetic interaction (increased substrate plasma concentration). Avoid co-administration.

Drugs Associated with QT Prolongation

Avoid co-administration of drugs with significant potential for QTc prolongation with pacritinib.

Specific Drugs and Foods

Drug

Interaction

Comments

Clarithromycin

Increased peak plasma concentrations (by 30%) and AUC (by 80%)

Contraindicated. Avoid concomitant use

Rifampin

Decreased peak plasma concentrations (by 51%) and AUC (by 87%)

Contraindicated. Avoid concomitant use

More about Pacritinib (systemic) (monograph) (Vonjo)

Dosage information
Pacritinib (systemic) (monograph) Side Effects
During pregnancy
Drug images
Side effects
Breastfeeding Warnings
Drug class: Drugs

Related treatment guides

Myelofibrosis
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by